D Cunningham, R Powles, J Malpas, N Raje, S … - British Journal of Haematology, 1998 - interscience.wiley.com High-dose chemotherapy (melphalan) with autologous marrow stem cell support
(AMSCS) results in high response rates in multiple myeloma (MM), with up to 50%
of patients achieving complete remission. However, these remissions are ... Cited by 136 - Related articles - BL Direct - All 5 versions
A Smith, F Wisloff, D Samson… - British journal of haematology, 2006 - jspinaldisorderstechs.com In 2001, guidelines for the diagnosis and management of myeloma were published
by the Guidelines Working Group of the UK Myeloma Forum (UKMF) on behalf of the
British Committee for Standards in Haematology (BCSH) (UK Myeloma Forum; ... Cited by 106 - Related articles - Cached - BL Direct - All 7 versions
- ►annals.org MW Kattan, Y Inoue, FJ Giles, M Talpaz, H … - Annals of internal medicine, 1996 - Am Coll Physicians Design: A decision analysis and Markov model that described the natural history
of the therapeutic process. The Markov model contained two treatment arms
(interferon- and hydroxyurea) and eight states of health (complete ... Cited by 43 - Related articles - BL Direct - All 4 versions
- ►hematologylibrary.org IMS Dahl, I Turesson, E Holmberg, K Lilja - Blood, 1999 - bloodjournal.hematologylibrary.org Serum from 386 myeloma patients were analyzed for serum hyaluronan (HYA) at
diagnosis. Median age was 68 years (range, 32 to 87 years). The distribution of
Ig classes was typical (58% IgG, 21% IgA, 1% IgD, and 20% light chain ... Cited by 24 - Related articles - BL Direct - All 5 versions
N Gulbrandsen, F Wisløff, L Brinch, K Carlson … - Medical Oncology, 2001 - Springer Page 1. Health-Related Quality of Life in Multiple Myeloma Patients Receiving
High-Dose Chemotherapy with Autologous Blood Stem-Cell Support ... Cited by 21 - Related articles - BL Direct - All 4 versions
N Gulbrandsen, MJ Hjermstad, F Wisloff - European journal of haematology, 2004 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 19 - Related articles - BL Direct - All 4 versions
N Gulbrandsen, F Wisloff, E Nord, S Lenhoff, M … - European journal of haematology, 2001 - interscience.wiley.com Abstract: We evaluated the costs and the cost utility of high-dose melphalan and
autologous stem cell support followed by interferon maintenance relative to
conventional treatment with melphalan and prednisone, in patients less than ... Cited by 19 - Related articles - BL Direct - All 6 versions
F Wisloff, N Gulbrandsen, M Hjorth, S Lenhoff … - European journal of haematology, 2005 - interscience.wiley.com Abstract: Earlier studies showing a negative impact of anaemia on quality of
life (QOL) lack adequate adjustment for confounding factors such as disease
stage and tumour response. We examined the impact of haemoglobin ... Cited by 13 - Related articles - BL Direct - All 4 versions
LM Knudsen, T Rasmussen, K Nikolaisen, HE … - European Journal of Haematology, 67, 2001 - interscience.wiley.com Abstract: Background: Cells belonging to the malignant clone are found in the
peripheral blood in myeloma patients. In order to minimise the content of tumour
cells in the stem cell product it is crucial to perform stem cell harvest ... Cited by 7 - Related articles - BL Direct - All 4 versions
MM Oken, T Leong, RE Lenhard Jr, PR Greipp, … - CA A Cancer Journal for Clinicians - interscience.wiley.com Interferon (IFN) has demonstrated activity in the treatment of patients with
multiple myeloma. A previous Eastern Cooperative Oncology Group (ECOG) study
suggested that the rates of complete response (CR) and survival were ... Cited by 7 - Related articles
